Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models
- 1Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA
- 2Department of Biology, Temple University, Philadelphia, PA, USA
- 3EyeCRO, Oklahoma, OK, USA
by Coroniti, R., Farjo, R., Nuno, D. J., Otvos, L., Scolaro, L., and Surmacz, E. (2016). Front. Mol. Biosci. 3:67. doi: 10.3389/fmolb.2016.00067
In the original article, the name of the author Rafal Farjo was misspelled as Rafal Fario.
The correct spelling appears above. The authors apologize for this error. This does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: leptin, ObR antagonist, peptide drug, VEGF, ocular neoangiogenesis
Citation: Coroniti R, Farjo R, Nuno DJ, Otvos L, Scolaro L and Surmacz E (2016) Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models. Front. Mol. Biosci. 3:75. doi: 10.3389/fmolb.2016.00075
Received: 26 October 2016; Accepted: 31 October 2016;
Published: 18 November 2016.
Edited and reviewed by: Ali Tavassoli, University of Southampton, UK
Copyright © 2016 Coroniti, Farjo, Nuno, Otvos, Scolaro and Surmacz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eva Surmacz, firstname.lastname@example.org